Here’s whether Ocular Therapeutix, Inc. (OCUL) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Caution.
🟡
Caution
Positives: 50-day MA is rising (+1.10% over 10 days); RSI 59 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative). Currently 45.6% off its 52-week high. Score: -1/7.
OCUL is trading below its 200-day MA ($10.58) — a key warning sign the longer-term trend is under pressure. An RSI of 59.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -0.1% compares to +22.9% for SPY (trailed the market by 23.0%). The current 45.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.
$10,000 invested 1 year ago→ $9,989 today
vs. S&P 500 (SPY) — same period trailed market by 23.0%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✗Above 200-day MA ($10.58)
✗Above 50-day MA ($8.95)
✓RSI(14) neutral zone (30–70) — currently 59.5
✗Positive return (-0.1%)
!Within 10% of period high (−45.6%)
Period Range $8.94
$6.23$16.44
RSI (14) 59.5
0 · OversoldOverbought · 100
Key Metrics
Price$8.94
Period Return-0.1%
Period High$16.44
Period Low$6.23
Drawdown−45.6%
MA-50$8.95
MA-200$10.58
RSI (14)59.5
Avg Volume (30d)2.7M
vs. SPYtrailed by 23.0%
Return Rank#699 of 1246
Trend Signals
Price is below the 200-day moving average ($10.58)